Unknown

Dataset Information

0

Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.


ABSTRACT: Liver gene transfer with adeno-associated viral (AAV) 2/8 vectors is being considered for therapy of systemic diseases like mucopolysaccharidosis type VI (MPS VI), a lysosomal storage disease due to deficiency of arylsulfatase B (ARSB). We have previously reported that liver gene transfer with AAV2/8 results in sustained yet variable expression of ARSB. We hypothesized that the variability we observed could be due to pre-existing immunity to wild-type AAV8. To test this, we compared the levels of AAV2/8-mediated transduction in MPS VI cats with and without pre-existing immunity to AAV8. In addition, since levels of lysosomal enzymes as low as 5% of normal are expected to be therapeutic, we evaluated the impact of pre-existing immunity on MPS VI phenotypic rescue. AAV2/8 administration to MPS VI cats without pre-existing neutralizing antibodies to AAV8 resulted in consistent and dose-dependent expression of ARSB, urinary glycosaminoglycan (GAG) reduction, and femur length amelioration. Conversely, animals with pre-existing immunity to AAV8 showed low levels of ARSB expression and limited phenotypic improvement. Our data support the use of AAV2/8-mediated gene transfer for MPS VI and other systemic diseases, and highlight that pre-existing immunity to AAV8 should be considered in determining subject eligibility for therapy.

SUBMITTER: Ferla R 

PROVIDER: S-EPMC3581049 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.

Ferla Rita R   O'Malley Thomas T   Calcedo Roberto R   O'Donnell Patricia P   Wang Ping P   Cotugno Gabriella G   Claudiani Pamela P   Wilson James M JM   Haskins Mark M   Auricchio Alberto A  

Human gene therapy 20130130 2


Liver gene transfer with adeno-associated viral (AAV) 2/8 vectors is being considered for therapy of systemic diseases like mucopolysaccharidosis type VI (MPS VI), a lysosomal storage disease due to deficiency of arylsulfatase B (ARSB). We have previously reported that liver gene transfer with AAV2/8 results in sustained yet variable expression of ARSB. We hypothesized that the variability we observed could be due to pre-existing immunity to wild-type AAV8. To test this, we compared the levels o  ...[more]

Similar Datasets

| S-EPMC3345988 | biostudies-literature
| S-EPMC4930586 | biostudies-literature
| S-EPMC5746592 | biostudies-literature
| S-EPMC6428272 | biostudies-literature
| S-EPMC2873242 | biostudies-literature
| S-EPMC5934473 | biostudies-literature
| S-EPMC8447860 | biostudies-literature
| S-EPMC3976509 | biostudies-literature
| S-EPMC9258286 | biostudies-literature
| S-EPMC7301175 | biostudies-literature